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ABSTRACT 
Cocaine use among opioid dependent persons is common , with an 
estimated 40 to 70% of those seeking treatment for opioid dependence, also 
using cocaine (Sullivan et al., 2011 ). The effects of cocaine use on treatment 
outcomes for those seeking medication assisted treatment (MAT) for opioid 
dependence are not well understood. Buprenorphine, prescribed under the brand 
name Suboxone, has recently emerged as a convenient, effective method of 
MAT. The Facilitated Access to Substance Abuse Treatment with Prevention And 
Treatment of HIV (FAST PATH) program at Boston Medical Center, is a research 
study to provide substance abuse treatment along with primary care and H IV 
risk-reduction counseling to those afflicted with these epidemics. The objective of 
this study was to determine the association of cocaine use with treatment 
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retention and opioid abstinence at six months for patients receiving 
buprenorphine in the FAST PATH program. 
A prospective cohort study was conducted on 116 patients enrolled in the 
FAST PATH program through 02/01/2012. Assessments were conducted at 
baseline and six months to evaluate the association between baseline cocaine 
use and treatment retention as well as opioid abstinence at six months. Baseline 
cocaine use was measured by either any urine toxicology screen positive for 
cocaine prior to study enrollment or 30 day self-reported cocaine use on the 
initial assessment. 
Of the 116 participants, 39% were positive for cocaine use at baseline and 
52% were HIV positive. Baseline cocaine use had no effect significant on 
treatment retention or opioid abstinence at six months. Among all the participant 
characteristics measured, there were no significant differences between the 
cocaine positive (n=45) and cocaine negative (n= 71) groups. In adjusted 
analysis, age was the only covariate which was significant at predicting the odds 
of treatment retention or opioid abstinence with a 1 .11 (p-value = 0.0003) and 
1.08 (p-value = 0.02) greater odds of each, respectively. Although cocaine use 
did not affect the dependent variables, integrated substance abuse and primary 
care clinics utilizing buprenorphine are a rich area of future research . Specifically, 
subsequent studies should determine how varied groups of opioid dependent 
persons perform within this framework, and the underlying characteristics 
moderating their outcomes. 
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INTRODUCTION 
The number of persons in the United States using prescription opioids and 
non-prescription opiates (i.e. heroin) for nonmedical purposes has increased 
dramatically in recent years. According to the National Epidemiologic Survey on 
Alcohol and Related Conditions, approximately 4.7% of the American population, 
or over 13 million individuals, have used prescription opioids for nonmedical 
purposes at least once in their lifetime (Huang et al., 2006). Similarly, an 
estimated 3.7 million individuals have used heroin at least once in their lifetime 
(Volkow, 2005). Although opioid dependence rates are far less than lifetime use 
rates, The National Consensus Development Panel on Effective Medical 
Treatment of Opiate Addiction (1998) estimated there are approximately 980,000 
current, long-term opioid users, with 600,000 being classified as opioid 
dependent. More recently, in 2005 the Substance Abuse and Mental Health 
Services Administration (Figure 1) estimated there were over 236,000 people in 
treatment for opioid dependence (Substance Abuse and Mental Health Services 
Administration [SAMHSA], 2006). This includes both maintenance and 
detoxification programs. Although over 1 ,000 substance abuse treatment 
facilities offered opioid dependence treatment in 2005, this represents fewer than 
8% of all substance abuse treatment facilities in the US (SAMHSA, 2006). These 
findings indicate there are a majority of opioid dependent persons who are in 
need of effective, accessible opioid treatment programs. 
Table 1 :US Citizens Receiving Methadone or Buprenorphine Therapy in 
2005 acording to the 2006 OASIS Report (SAMHSA, 2006) 
Methadone Buprenorphine 
Total# Median# Total# Median# % of 
of of Clients % of of of Clients Type of Clients Clients per Clients Clients per Program Facility Facility 
Total 100 235,836 199 100 1 '165 5 
Maintenance 40 95,058 230 25 288 5 Only 
Detoxification 1 2,131 10 10 112 4 Only 
Maintenance 
and 59 138,647 205 65 765 5 
Detoxification 
Opioid use has been associated with negative psychological , health , and 
behavioral patterns which increase the need for appropriate treatment options. 
For example, an association between lifetime mood and anxiety disorders, and 
lifetime prevalence of prescription opioid disorders was identified in 2006 
(Conway, Compton , Stinson, & Grant, 2006). Additionally, heroin use has been 
associated with increased HIV risk factors, including having multiple partners, 
injection drug user (IOU) partners, and lack of condom use (Zhao et al. , 2006) . 
IDUs were also more likely to develop opportunistic infections (Roy et al. , 2011 ). 
Among persons living with HIV in the US, 18.5% were IDUs and an additional 5% 
were IDUs who also engaged in male-to-make sexual contact (Centers for 
Disease Control and Prevention [CDC], 2008) . Additionally, non-injection drug 
use has been associated with an increased risk of H IV progression to AIDS 
(Kipp, Desruisseau, & Qian, 2011 ). Length of heroin use has also been found to 
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increase risk of contracting Hepatitis C virus (HCV) (Baa et al. , 2011 ). HCV 
infection has been independently associated with an increased risk of H IV among 
I DUs (Backmund et al. , 2005) . 
Furthermore, the economic burden to society due to increased opioid 
abuse has risen disproportionately to the number of opioid dependent persons. 
Birnbaum, et al. estimated in 2009 the societal costs of prescription opioid abuse 
and dependence alone was over $55.7 billion, divided among workplace costs 
(46%), healthcare costs (45%) , and criminal justice costs (9%) (Birnbaum et al. , 
2011 ). 
Compounding the consequences of opioid dependence is the high 
mortality rate associated with both prescription and nonprescription opioid use. 
Over the last decade, morbidity rates associated with prescription opioid 
overdose have risen dramatically in the US. In 2000, the death rate from an 
overdose of painkillers was 4,000 persons; however, in 2007, that number was 
reported at more than 11 ,000 individuals (Devi , 2011). In contrast, the death rate 
associated with heroin overdose has remained steady during this time at 2,000 
individuals per year (Devi , 2011 ). In January 2012, the CDC reported that for 
every one "unintentional overdose death related to an opioid analgesic, nine 
persons are admitted for substance abuse treatment, 35 visit emergency 
departments, 161 report drug abuse or dependence, and 461 report nonmedical 
uses of opioid analgesics" (CDC, 2012). 
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Despite the recognized need for opioid addiction treatment programs, 
numerous barriers to access of addiction treatment have been identified. These 
include regulatory requirements and procedures, lack of medical insurance, 
aversion to substance abuse treatment due to individual beliefs, homelessness, 
slow admissions process to substance abuse facilities, full capacity at substance 
abuse facilities, as well as a belief of societal or legal repercussions (i.e. loss of 
child custody) if they enrolled in an addiction treatment program (Appel , Ellison, 
Jansky, & Oldak, 2004) . 
Once enrolled , treatment options for opioid dependent persons have 
shown significant reductions opiate use, as well as in the negative behaviors 
associated with opiate use. Current treatment options include detoxification 
programs, methadone maintenance therapy (MMT) , office-based treatment 
(OBOT) with buprenorphine, and behavioral therapies (Volkow, 2005) . As an 
established treatment for opioid dependence, MMT has been shown to decrease 
H IV risk behaviors, decrease number of sexual partners, and reduce the 
frequency of opiate use among those retained in treatment (Wells , Calsyn , Clark, 
Saxon, & Jackson, 1996). Retention in MMT has been predicted by older 
participant age, non-black race, and higher methadone dosage, among other 
factors (Saxon , Wells, Fleming, Jackson, & Calsyn , 1996). Although MMT has 
been shown as a highly effective treatment option, office-based treatments have 
recently emerged which provide greater flexibility and fewer barriers to access, 
thus increasing the likelihood of treatment engagement and retention. 
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Buprenorphine, a partial opioid agonist, has been shown over the last 
decade to be an effective opioid-agonist treatment modality and alternative to 
MMT (Volkow, 2005). Buprenorphine is a partial 1-1-opioid agonist and K-opioid 
antagonist, which has been shown to have less abuse potential than methadone 
(Connock et al., 2007) . This is due to its comparatively lower rewarding effect 
and a ceiling effect present at high doses (Walsh, Preston, Stitzer, Cone, & 
Bigelow, 1994). A recent study integrating a buprenorphine OBOT program into 
the San Francisco Public Health System found that 61% of participants were 
retained in treatment after one year (Hersh, Little, & Gleghorn , 2011) . In addition , 
urine toxicology screens positive for opioid use fell to just 16% after the first six 
months of treatment. Other studies have shown similar reductions in opioid use 
in buprenorphine OBOT programs; however, these reductions are usually lost 
once buprenorphine is discontinued (Weiss et al. , 2011 ). Other studies have 
found a difference in treatment engagement among prescription and 
nonprescription opioid users in buprenorphine OBOT programs, with those using 
heroin performing worse than those dependent on prescription opioids (Weiss et 
al. , 2011 ). 
Similar reductions in opioid use have been identified in HIV-positive 
participants receiving buprenorphine OBOT. Lucas, et al (201 0) found that HIV-
positive patients were more likely (74% versus 41 %) to participate in treatment 
than those referred to case-management or other opioid treatment programs. 
Additionally, the buprenorphine OBOT participants had more HIV care visits than 
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those in the referral group, although there was no difference observed in 
antiretroviral therapy (ART) rates, CD4 counts, or viral load between groups 
(Lucas et al. , 201 0). In contrast, other studies have found significant differences 
in HIV outcomes between participants in buprenorphine OBOT versus no opioid 
treatment program. A multi-site, cross-sectional study of opiate-dependent 
participants found those who received buprenorphine OBOT had greater 
improvements in CD4 counts and were more likely to initiate ART than those 
receiving alternative treatments (Altice et al. , 2011 ). Additionally, retention in this 
particular OBOT program was associated with increased viral suppression. 
As part of OBOT buprenorphine programs, behavioral counseling has also 
been associated with increased treatment success and retention . In one study of 
polydrug users (both heroin and cocaine use at enrollment) in a 70 day 
buprenorphine OBOT program with cognitive-behavioral counseling , there was 
an observed inverse relationship between the number of counseling sessions 
during the first nine weeks of treatment and the presence of cocaine or opioids in 
urine toxicology screens during week 10 (Montoya et al. , 2005). Also, across all 
buprenorphine dosages, the importance of counseling sessions grew more 
predictive of treatment success as the study progressed (Montoya et al ., 2005) . 
Comparisons have been drawn between MMT and buprenorphine OBOT 
programs to determine what differences, if any, exist in treatment retention and 
opiate abstinence between the two therapies. In one controlled clinical trial , 
participants were randomized to either MMT or buprenorphine OBOT, both with 
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counseling sessions, for 12 weeks (Mattick et al. , 2003) . This study found that 
participants randomized to the MMT group had greater initial retention at four 
weeks as compared to those in buprenorphine OBOT; however, this difference 
was eliminated by the end of the study. Additionally, those patients who 
completed the 12 week OBOT program had higher rates of depression than 
those who failed to complete the entire program (Mattick et al. , 2003) . Other 
studies have shown an increase in opiate abstinence in 12 weeks buprenorphine 
OBOT versus MMT and greater employment for participants in the OBOT 
program (Mattick et al. , 2003) . Furthermore, as compared with other opiate 
dependence treatment programs, a buprenorphine OBOT program was found to 
increase six out of 16 quality control measures for HIV treatment. These include 
increased CD4 monitoring, IOU counseling, and HIV clinical visits (Korthuis et al. , 
2011 ). The high success rates in buprenorphine OBOT programs have increased 
their prevalence across the US as an effective opioid-agonist treatment option . 
Among those seeking treatment for opioid dependence, polydrug use is a 
frequent issue which can affect treatment success. In particular, cocaine use is 
frequently found in patients who are also opioid-dependent. It is not uncommon 
for 50-70% of participants seeking treatment for opioid dependence to be positive 
for both opiates and cocaine at treatment onset (Leri , Bruneau, & Stewart, 2001 ; 
Sullivan et al. , 2011). Cocaine use has been investigated previously in MMT, and 
more recently, buprenorphine OBOT programs. Although the association 
between cocaine use, treatment retention and opioid abstinence has been 
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investigated, there is not a consensus among researchers as to the extent of the 
association. Previous studies have determined baseline cocaine use is an 
independent predictor of poor treatment outcomes, including prolonged heroin 
use, incarceration , needle sharing, and a lack of employment (Williamson, Darke, 
Ross, & Teesson , 2007). This same study found baseline cocaine users were 
also less likely to achieve opioid abstinence during treatment, both in MMT and 
buprenorphine OBOT programs (Williamson et al. , 2007) . In studies investigating 
the association between baseline cocaine use and buprenorphine OBOT 
treatment retention , poor retention and a smaller percentage of continuous 
opioid-negative urines throughout treatment have been associated with cocaine 
use (Sullivan et al. , 201 0) . Additionally, patients with baseline cocaine use had 
higher rates of "drug use, legal and psychiatric problems" (Sull ivan et al. , 201 0) . 
This study was limited, however, because the effect of counseling , both group 
and individual counseling was not taken into consideration when determining the 
association between baseline cocaine use and treatment retention . 
Subsequent studies have attempted to replicate these findings with 
exclusively HIV-positive cocaine users. In 2011 , Sullivan et al. , showed baseline 
cocaine use was a strong predictor (1 .5 times more likely) of in-treatment opioid 
use in a buprenorphine OBOT program. In contrast to previous research , 
however, baseline cocaine use had no effect on treatment retention in an HIV-
positive population (Sullivan et al. , 2011 ). Differences in findings among 
buprenorphine studies could be due to a difference in study design. For example, 
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both of the previous studies used self-reporting to determine baseline cocaine 
use, rather than urine toxicology screens (Sullivan et al. , 201 0; Sullivan et al. , 
2011 ). This could lead to under-reporting of baseline cocaine use for all 
participants. OBOT programs may require participants to test negative for 
cocaine use prior to initiation of buprenorphine treatment. This could delay the 
time between identifying a possible participant and their first buprenorphine 
prescription, which could have subsequent effects on treatment initiation , 
engagement and retention, as well as opioid abstinence. 
Recognizing the need for expanded opioid dependence treatment, the 
Facilitated Access to Substance Abuse Treatment with Prevention And 
Treatment of HIV (FAST PATH) was started at Boston Medical Center in 2008. 
This program was funded by a SAMHSA grant award to expand substance 
abuse treatment in conjunction with HIV/AIDS services for communities affected 
by these twin epidemics. This program is operated out of the Section of General 
Internal Medicine and Center for Infectious Diseases Outpatient Clinic at Boston 
Medical Center (BMC). The FAST PATH program is designed to coordinate and 
integrate previously fragmented services for participants in need of opioid 
dependence treatment, HIV/AIDS care, primary care services, and HIV risk 
reduction counseling. Participants with opioid dependence are offered 
buprenorphine OBOT or MMT and have regular visits with the coordinated clinic 
staff to assess progress, perform urine toxicology screens, provide primary care 
services, as well as HIV/AIDS care and risk reduction counseling , as needed. 
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Participants also attend individual or group counseling sessions as part of the 
OBOT buprenorphine program. Treatment retention and 30 day opioid use are 
evaluated at baseline and six months after starting buprenorphine treatment in 
the FAST PATH program. 
The objective of this analysis is to identify and describe cocaine use, as 
defined as opioid dependence and cocaine use upon initiation into the FAST 
PATH program, among those patients seeking treatment with buprenorphine. 
Specifically, this research is concerned with whether cocaine use prior to starting 
buprenorphine therapy is associated with decreased six-month retention or past 
30 day opioid abstinence at six months. Furthermore, this research is designed 
to identify factors which moderate the association between cocaine use and six-
month treatment retention and past 30 day opioid abstinence at six months. 
These findings have direct implications to current buprenorphine OBOT 
programs in evaluating the study policies and practices that increase retention 
and abstinence of cocaine users. 
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METHODS 
FAST PATH PROGRAM DESCRIPTION 
Patients for the FAST PATH program were recruited from primary care 
providers, residential substance abuse treatment programs, outreach centers, 
and direct referrals within Boston , MA. Figure 2 displays the overall participant 
flow through the FAST PATH program, from referral to substance abuse 
treatment. Participants were enrolled into the program following an eligibility 
screening phone consultation with a FAST PATH staff member. Program 
eligibility was based on results of the FAST PATH Screening Form administered 
during this consultation. Eligible participants were positive for all of the criteria in 
Table 2. 
Table 2 : FAST PATH Program Eligibility Criteria 
FAST PATH 
Active alcohol or drug dependence 
Program High risk for transmitting HIV or contracting HIV due to risk drug 
Eligibility or sex behaviors 
Criteria 
Willing to receive medical care at BMC 
Eligible participants were enrolled in the study following an initial meeting 
with a FAST PATH staff member to determine past 30 day substance use 
frequency and type, health concerns, social connectedness, and demographic 
information. A standardized Government Performance and Results Act interview 
form (GPRA) was administered by a trained FAST PATH staff member to each 
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participant. Following enrollment, patients were divided into two clinical service 
areas, HIV Care Team or Primary Care Team, based on their HIV status (Figure 
1 ). Both provider teams were staffed by a physician (MD), nurse (RN) , and 
addiction counselor (AC); however, patients were treated within different 
departments at BMC: the HIV Care Team was located in the Center for Infectious 
Disease and the Primary Care Team was located in the Section of General 
Internal Medicine. Participants also provided a urine sample at this time for 
toxicology screening. 
On the initial visit, the FAST PATH coordinated team performed a FAST 
PATH Comprehensive Assessment to evaluate opioid dependence, HIV risk 
factors, and overall health status. Each opioid dependent patient worked with the 
MD to determine whether MAT, including MMT and buprenorphine OBOT, was 
appropriate for the management of their opioid dependence. Buprenorphine was 
prescribed under the brand name Suboxone. Patients receiving buprenorphine 
had weekly visits initially with the clinic staff to adjust dosage in order to 
adequately manage their opioid dependence. Patients also received group 
counseling and/or individual counseling with the FAST PATH AC, as necessary, 
throughout the study period to help manage their substance use. Topics of 
discussion in the group counseling sessions were determined by the specific 
providers and group members. 
Participants were closely followed for the treatment period by the 
coordinated clinic staff, with regularly scheduled visits with the MD, RN, and AC 
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as determined by the specific provider. During their maintenance throughout the 
program, participants were expected to engage in primary care visits at BMC, 
either with the FAST PATH physician or their personal primary care physician . A 
second assessment interview was conducted five to eight months after the initial 
interview using the same format as the baseline GPRA. 
Participants were not discharged following the study period since the 
FAST PATH program was embedded within primary care and operates 
longitudinally like primary care. 
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Figure 1: FAST PATH Participant Flowsheet 
HUMAN SUBJECTS PROTECTION 
The research protocol for this prospective cohort study was reviewed and 
approved by the Institutional Review Board at Boston Medical Center and Boston 
University School of Medicine. 
STUDY DESIGN AND POPULATION 
Data analysis was performed on 116 patients enrolled in the FAST PATH 
program at BMC through 02/01/2011 who also met the required eligibility criteria. 
Patients must have had a FAST PATH treatment visit within 30 days before or 
after their baseline GPRA was administered. The inclusion criteria are listed in 
Table 3. 
Table 3: Study Inclusion Criteria 
Inclusion Criteria Result: 
Buprenorphine Must occur within 30 days before or after Baseline 
Prescription GPRA interview 
FAST PATH visit Must occur within the 30 days before or after 
Baseline GPRA interview 
DATA COLLECTION AND MEASUREMENT 
A baseline GPRA was administered to each study participant following 
enrollment. The findings from this assessment were used to determine past 30 
day opioid use and cocaine use for their baseline values. After six months in the 
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study, an identical follow-up GPRA was administered to all participants to identify 
opioid abstinence as defined by no opioid use in the past 30 days. 
OUTCOME VARIABLES 
There were two main dependent variables for this study: treatment 
retention and opioid abstinence. Retention was measured over the180 days after 
the first buprenorphine prescription , whereas abstinence was measured at the 
GPRA follow-up. Treatment Retention was defined as no absences in contact 
with the FAST PATH clinic staff for greater than 30 days during the study period. 
Opioid Abstinence was defined as no opioid use in the past 30 days as reported 
on the follow-up GPRA administered at six months. 
Initiation and Engagement, as defined per the Washington Circle (1./VC 
2007) guidelines described in 2007, were also included in the data analysis. 
Initiation was defined as a second FAST PATH clinic visit within 14 days of study 
enrollment. Engagement was defined as two additional FAST PATH clinic visits 
within 30 days of Initiation. 
INDEPENDENT VARIABLES 
The independent variable identified as possibly contributing to the study 
outcome was Baseline Cocaine Use. A participant "positive" for this variable must 
have reported either of the following , A) any cocaine-positive urine toxicology 
tests prior to initiating buprenorphine, and/or B) self-reported cocaine use during 
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the past 30 days as indicated on the baseline GPRA. Urine toxicology screens 
for Baseline Cocaine Use were administered to each participant at the time of 
study enrollment. Per FAST PATH program policy, study participants must 
achieve at least one negative urine toxicology screen for cocaine prior to 
receiving their first buprenorphine prescription. 
COVARIATES 
Additionally, data in the following categories were gathered on the 
baseline GPRA administered for each participant. These data were used as 
covariates to explore whether they moderated the association between cocaine 
use and the dependent variables. Table 4 lists the covariates used in this 
analysis. Treatment Episode was defined as occurring if the buprenorphine 
prescription had not been continued for seven days past the last dose of the 
prescription. 
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Table 4: Potential Covariates to Baseline Cocaine Use among Patients 
Receiving Buprenorphine in a Coordinated Substance Abuse and Primary 
Care Treatment Program 
• Age 
• Race 
• Gender 
Demographic • Employment 
• Education 
• Housing 
• 30 day self -reported arrest 
• H IV Positive vs. H IV Negative 
Clinical 30 day self-reported serious depression • 
• 30 day self-reported other drug use 
Substance Use 30 day self-reported alcohol use • 
• Number of individual counseling sessions 
• Number of group counseling sessions 
Program 
• Number of urine toxicology screens 
• Number of treatment episodes 
STATISTICAL ANALYSIS 
Statistical analyses were performed on all descriptive variables in the 
study. Frequencies and proportions were determined for all categorical variables. 
Also, mean, standard deviation, median, range, and interquartile range were 
determined for all continuous variables. A Spearman correlation matrix was 
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created to evaluate potential co-linearity, using a correlation co-efficient cutoff (r 
= 0.4) among cocaine use and covariates. No co-linearity was identified among 
the variables, thus logistic regression models were created to determine if 
correlation existed among the dependent variables, cocaine use and covariates. 
Logistic regression models were fit for cocaine use and each of the covariates for 
the four outcomes of interest, producing unadjusted odds ratio. To focus the 
analysis of this study, the covariates were ranked in order of priority to determine 
which would be included in the adjusted analysis. The ranking was based on a 
prior literature review and the clinical experience of the FAST PATH staff, and 
the following variables were determined to be of the most relevance to the 
project: HIV Positive, Race, Age, and Gender. The dependent variables, Opioid 
Abstinence, Treatment Retention, Initiation and Engagement, were compared in 
the adjusted analysis with cocaine use at baseline and the primary covariates at 
a= 0.05 with a 95% confidence interval. 
19 
RESULTS 
PARTICIPANT CHARACTERISTICS 
The demographic and clinic characteristics of the 116 patients included in 
this study are listed in Table 5. Of the 116 study participants, the average age 
was 42.4 years , 31% were female, and 53% were HIV positive. The participants' 
races were 34% Hispanic, 16% Non-Hispanic Black, 4% Non-Hispanic Other and 
45% Non-Hispanic White, respectively. Non-Hispanic black subjects were 
marginally more likely to be cocaine positive rather than cocaine negative with 
22% versus 13%, respectively. Additionally, a majority of the participants, 101 out 
of 116, or 87%, had reported serious depression in the previous 30 days. The 
majority of the participants, 76% had housing upon enrollment to the study, and 
69% had education greater than or equal to the 121h grade. Only 14 subjects 
were employed , either full time or part time, during the study; however, among 
those employed the majority, 86%, were cocaine negative. 
Slightly less than half of the participants reported any alcohol or other drug 
use during the previous 30 days, 39% and 47%, respectively. There was a 
marginal difference between the two cohorts in their alcohol use, with 53% of the 
cocaine positive subjects versus only 30% of the cocaine negative subjects 
reporting alcohol use in the previous 30 days Only 4 participants reported an 
arrest by law enforcement in the previous 30 days. 
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COCAINE USE AMONG PARTICIPANTS 
Of the 116 participants, 45 (39% of the total) were positive for cocaine use 
at baseline, as defined as either a positive urine toxicology screen at baseline or 
a positive self-report of cocaine use in the past 30 days on the baseline GPRA. 
Among all the participant characteristics measured, there were no significant 
differences between the cocaine positive (n=45) and cocaine negative (n= 71) 
groups. Table 7 indicates the distribution of participants who reported cocaine 
positive at baseline, stratified by GPRA report or urine toxicology screen . Eight 
participants, 6.9% of the total study sample, self-reported negative for cocaine 
use, but had positive urine toxicology screens for cocaine. The remainder of the 
participants had congruent self reports and urine toxicology screens based on 
the window of time cocaine was detectable in urine. 
HIV STATUS WITHIN POPULATION 
There was not a significant difference in cocaine use at baseline between 
those participants who were HIV positive and those who were HIV negative. Of 
the 116 participants included, 52% or 61 individuals self-identified as being HIV 
positive. This group was split evenly between the two cohorts with 29 individuals, 
or 64% of the cocaine positive group and 32 individuals, or 45% of the cocaine 
negative group. Furthermore, in the adjusted analysis, HIV status did not 
moderate any association between the dependent variables and the covariates. 
21 
1\) 
1\) 
Table 5 : Participant Characteristics, Overall and by Cocaine Use (N=116) 
All patients Cocaine Neg. 
Participant Characteristic (N=116) (N=71) 
% (n/N) % (n/N) 
Age - Mean (SO) 42 (9.85) 43 (9.86) 
Percent Female 31% (36/116) 27% (19/71) 
Race- Hispanic 34% {40/116) 37% (26/71) 
- Non-Hispanic black 16% (19/116) 13% (9/71) 
- Non-Hispanic other 4% {5/116) 6% {4/71) 
- Non-Hispanic white 45% (52/116) 45% (32/71) 
H IV Positive 53% (61 /116) 45% (32/71) 
Housed 76% (88/116) 79% (56/71) 
Any Employment 12% (14/116) 17% (12/71) 
Completed 12th grade or higher 69% (80/116) 72% (51/71) 
Any alcohol use past 30 day 39% {45/116) 30% (21/71) 
Other drug use past 30 day 4 7% {54/116) 46% (33/71) 
Arrested past 30 day 3% (4/116) 3% (2/71) 
Mental Illness Diagnosis 87% (101/116) 86% (61/71) 
Cocaine Pos. 
(N=45) 
% (n/N) 
41 (9.88) 
38% (17/45) 
31% (14/45) 
22% (1 0/45) 
2% (1/45) 
44% (20/45) I 
64% (29/45) ! 
71% (32/45) 
4% (2/45) 
64% (29/45) 
53% {24/45) 
• 
47% (21/45) 
' 
4% (2/45) 
89% {40/45) 
1\.) 
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Table 6: Treatment Characteristics, Overall and by Cocaine Use (N=116) 
All patients Cocaine Neg. 
Treatment Characteristic (N=116) (N=71) 
% (n/N) % (n/N) 
Prescribed Buprenorphine for 30 days 84 (91/116) 87 (62/71) 
Prescribed Buprenorphine for 90 days 65 75/116) 69 (49/71) 
Prescribed Buprenorphine for 180 days 46 (53/116) 51 (36/71) 
Individual Counseling- Mean (SD) 5.16 (4.86) 5.18 (4.48) 
Group Counseling - Mean (SD) 6.06 (6.68) 6.61 (7.03) 
#Treatment Episodes- Mean (SD) 1.18 (0.41) 1.17 (0.41) 
Number of Urine Screens - Mean (SD) 10.9 (6.88) 10.6 (6.37) 
Proportion of Neg Urine Screens - Mean (SD) 0.65 (0.37) 0.68 (0.36) 
Days prescribed Buprenorphine - Mean (SD) 122 (67.9) 130 (64.5) 
Retention 36 (42/116) 37 (26/71) 
Abstinence 70 (68/98) 70 (39/56) 
Initiation of Treatment 87 (101/116) 86 (61 /71) 
Engagement in Treatment 76 (88/116) 75 (53/71) 
Cocaine Pos. 
(N=45) 
% (n/N) 
78 (35/45) 
58 (26/45) 
38 (17/45) 
5.11 (5.46) 
5.20 (6.06) 
1.20 (0.40) 
11.3 (7.68) 
0.61 
_(0.38J 
110 (71 .9) 
36 (16/45) 
69 (29/42) 
89 (40/45) 
78 (35/45) 
Table 7 : Baseline Cocaine Use among Patients Receiving Buprenorphine 
in a Coordinated Substance Abuse and Primary Care Treatment Program 
Stratified by Reporting Method, Self-Report versus Urine Toxicity (N=116) 
30 Day Cocaine Urine Toxicity Cocaine 
(GPRA: Positive Use of (Any Positive Urine Toxicology 
Cocaine in past 30 days) Screen for Cocaine at Baseline) 
No Yes Total 
No 71 8 79 
Yes 25 12 37 
Total 96 20 116 
BUPRENORPHINE PRESCRIPTION CHARACTERISTICS 
All of the participants were prescribed buprenorphine as part of their study 
inclusion. The average length of days prescribed buprenorphine was 122 +/- 67.9 
days during the 180 day study period. There was no significant difference 
between the cocaine positive and cocaine negative cohorts in the number of 
days prescribed buprenorphine. 46% of the participants were prescribed 
buprenorphine for all 180 days of the study period, while 65% were prescribed 
buprenorphine for at least 90 days and 84% were prescribed buprenorphine for 
at least 30 days. A smaller percentage of participants in the cocaine positive 
cohort were prescribed buprenorphine for the entire 180 days study period than 
in the cocaine negative group, 38% versus 51% , respectively; however, this 
difference was not significant. 
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FAST PATH TREATMENT CHARACTERISTICS 
Each participant received periodic visits with the FAST PATH clinic staff 
as determined by their specific providers. Both the cocaine positive and cocaine 
negative cohorts averaged 5.11 and 5.18 individual counseling visits, 
respectively, as well as 5.20 and 6.61 group counseling visits, respectively, 
during the study period. There was no significant difference in visits between the 
two cohorts. Furthermore, the number of treatment episodes, as defined as a 
seven day or greater lapse in their buprenorphine prescription , was rare for both 
cohorts, with the cocaine positive cohort reporting a mean of 1 .20 and the 
cocaine negative cohort reporting a mean of 1 .17 treatment episodes during the 
study period. 
Urine toxicology screens were administered periodically to all participants 
as part of the program requirements. There was an average of 10.9 urine 
toxicology screens administered over the study period and there was no 
significant difference between the two cohorts as to the number of screens 
administered. Additionally, the proportion of negative urine toxicology screens, as 
defined as urine toxicology screens negative for opioids and positive for 
buprenorphine as measured as the percent negative out of the total number of 
urine screens performed over the study period, was similar in both cohorts. 
25 
STUDY OUTCOMES 
OP/010 ABSTIENCE OUTCOMES 
Opioid abstinence, as measured by self-report on the follow-up GPRA, 
was one of two main outcome variables of this study. Opioid abstinence could 
not be assessed in 18 of the participants due to missing data on the follow-up 
GPRA. Of the 98 participants analyzed, 68 were opioid abstinent at six months, 
39 participants in the cocaine negative cohort and 29 in the cocaine positive 
cohort (Table 8). There was no significant difference in the rate of opioid 
abstinence between those who were cocaine positive and those who were 
cocaine negative, with 69% and 85% abstinent, respectively. 
In the adjusted analysis, the probability of opioid abstinence was not 
predicted by the independent variable, Cocaine Positive (Table 8). The only 
primary covariate shown to be significant in predicting opioid abstinence was 
participant age, with each one year increase in participant age to correlate with a 
1.08 greater odds of being opioid abstinent (p-value = 0.02). None of the other 
primary covariates were shown to significantly predict the odds of being opioid 
abstinent at six months. 
TREATMENT RETENTION OUTCOMES 
Treatment retention was defined as no absences in contact with the FAST 
PATH clinic staff for greater than 30 days during the study period. Treatment 
retention was assessed in all 116 study participants (Table 9). Of these 
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participants, 42 (36%) met the criteria for retention, 26 in the cocaine negative 
cohort and 16 in the cocaine positive cohort. There was no significant difference 
in retention between the cocaine positive and cocaine negative participants with, 
36% and 37% retained, respectively. 
In the adjusted analysis, the independent variable was not significant in 
predicting the odds of a participant being retained at six months (1.15, p-value = 
0. 7). As for opioid abstinence, the only covariate which was significant in 
predicting the odds of treatment retention was participant age, with a one year 
increase in age being associated with a 1 .11 increase in the odds of being 
retained (p-value = 0.0003) (Table 9). 
STUDY /NIT/A TION OUTCOMES 
Study initiation was defined according to the Washington Circle 
performance measurement, as an individual who had a second FAST PATH visit 
within 14 days of enrollment. Initiation was measured in all 116 study 
participants, and 101 were identified as having initiated into the program, 40 
participants in the cocaine positive cohort and 61 in the cocaine negative cohort 
(Table 6). There was no significant difference in initiation between the two 
cohorts with 89% initiation in the cocaine positive group and 86% initiation in the 
cocaine negative group. 
In the adjusted analysis, the independent variable, cocaine use, was not 
significant in predicting a change in the probability of being initiated into the 
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FAST PATH program with a p-value of 0.6 {Table 8). Furthermore, none of the 
primary covariates were able to significantly predict a change in the likelihood of 
a participant being initiated in either of the cohorts. 
STUDY ENGAGEMENT OUTCOMES 
Study engagement was defined as those participants who were initiated 
into the FAST PATH program and had two additional visits with the FAST PATH 
clinical team within 30 days of initiation. Engagement was measured in all 116 
participants, and 88 were found to have engaged with the program (Table 6). 
There was no significant difference in engagement between the cocaine positive 
and cocaine negative groups, with 78% and 75% having met the requirements 
for engagement. 
In the adjusted analysis, the independent variable did not predict a change 
in the probability of achieving Engagement with a p-value of 0.6 (Table 11 ). 
Furthermore, none of the primary covariates were able to significantly predict a 
change in the likelihood of a participant being engaged in the FAST PATH 
program. 
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Table 8: Unadjusted and Adjusted Odds Ratios of Opioid Abstinence at Six Months for Patients receiving 
Buprenorphine in a Coordinated Substance Abuse and Primary Care Out-Patient Treatment Program 
Opioid Abstinence Unadjusted Odds Ratio Adjusted Odds Ratio 
X (95% Cl) p-value X (95% Cl) p-value 
Cocaine: yes vs. no 0.97 (0.41 ,2.31) 0.9 1.00 (0.39,2.56) 1.0 
HIV: yes vs. no 1.74 (0.73 ,4.13) 0.2 1 .44 (0.48,4.29) 0.5 
Race: White vs. Non-White 0.84 (0 .35,2.02) 0.7 0.47 (0 .16, 1.35) 0.2 
Female: yes vs. no 0.77 {0 .31 ,1.90) 0.6 1 .18 (0.38,3.60) 0.8 
Age 1.07 (1 .02, 1 .12) 0.01 1 .08 (1 .01 , 1 .15) 0.02 
Housing 1.17 (0.42,3.29) 0.8 
Education 1.12 (0.45,2.80) 0.8 
Employment 0.75 (0.20,2.77) 0.7 
30 day alcohol use 1.54 (0.64,3.71) 0.3 
Mental Illness Diagnosis 0.37 (0.08, 1.78) 0.2 
Individual Counseling Sessions 1 .13 (1 .02, 1 .25) 0.02 
Group Counseling Sessions 1.15 (1 .05, 1 .26) 0.003 
Number of Treatment Gaps 0.80 (0 .30,2.12) 0.7 
Number of Urine Screens 1 .11 (1 .03, 1 .20) 0.0 
30 day other drug use 1.39 (0.58,3.29) 0.5 
Proportion of Neg. Urine Screens 6.23 (1 .85,20.94) 0.003 
Days Prescribed Buprenorphine 1.01 (1 .00,1.01) <0.0001 
w 
0 
Table 9: Unadjusted and Adjusted Odds Ratios of Treatment Retention at Six Months for Patients receiving 
Buprenorphine in a Coordinated Substance Abuse and Primarv Care Out-Patient Treatment P 
Treatment Retention Unadjusted Odds Ratio Adjusted Odds Ratio 
X (95% Cl) p-value X (95% Cl) p-value 
Cocaine: yes vs. no 0.5 (0.44,2.08) 0.9 1.150 (0.489,2. 702) 0.7 
HIV: yes vs. no 0.85 (0.40, 1.81) 0.7 0.542 (0 .212, 1.384) 0.2 
Race: White vs. Non-White 0.72 (0.34, 1.54) 0.4 0.452 (0.180,1.131) 0.09 
Female: yes vs. no 0.99 (0.44,2.25) 1.0 2.108 (0 .785,5.662) 0.1 
Age 1 .06 (1 .02, 1.11) 0.01 1 .1 08 (1 .048, 1 .172) 0.0003 
Housing 0.69 (0.29, 1.64) 0.4 
Education 1.73 (0.74,4.08) 0.2 
Employment 0.98 (0.3,3.13) 1.0 
30 day alcohol use 0.95 (0.44,2.08) 0.9 
Mental Illness Diagnosis 0.83 (0.27,2.52) 0.7 
Individual Counseling Sessions 1 .36 (1 .2, 1.52) <0.0001 
Group Counseling Sessions 1.27 (1 .16, 1.4) <0.0001 
Number of Treatment Episodes 0.26 (0.07,0.94) 0.04 
Number of Urine Screens 1.38 (1.23, 1.54) <0.0001 
30 day other drug use 1.44 (0.67,3.09) 0.3 
Proportion of Neg. Urine Screens 39.3 (6.71 ,230.4) <0.0001 
Days Prescribed Buprenorphine 1.03 (1 .02, 1.04) <0.0001 
Table 10: Unadjusted and Adjusted Odds Ratios of Initiation for Patients receiving Buprenorphine in a 
Coordinated Substance Abuse and Primarv Care Out-Patient Treatment P 
- - · - - -----
-,------ -- - - - - - - ~- ----
Initiation Unadjusted Odds Ratio Adjusted Odds Ratio 
x_{95% Cl) p-value X (95% Cl) p-value 
Cocaine: yes V!5. no 1 ~31 (0.42,4.12) 0.6 1.46 (0.44,4.82) 0.5 
HIV: yes vs. no 0.71 (0 .23,2.13) 0.5 0.54 (0.15,1.98) 0.4 
Race: White vs. Non-White 2.02 (0.67,6.11) 0.2 3.00 (0.87, 1 0.32) 0.1 
Female: yes vs. no 0.89 (0 .28,2.81) 0.8 0.81 (0.25,3.01) 0.7 
Age 0.98 (0.93, 1.04) 0.6 0.97 (0 .91 '1.04) 0.4 
Housing 1.17 (0.34,4.00) 0.8 I 
Education 0.78(0.23,2.65} 0.7 I 
Employment 2.07 (0.25, 17.1) 0.5 
w 
30 day alcohol use 1.31 (0.42,4.12) 0.6 
....... 
Mental Illness Diagnosis 1 .04 (0.21 ,5.15) 1.0 
i Individual Counseling Sessions 0.95 (0.85,1.05) 0.3 I 
I 
Group Counseling Sessions 0.99 (0.92, 1.08) 0.9 
Number of Treatment Episodes 0.88 (0.24,3.18) 0.8 
Number of Urine Screens 1.00 (0.92, 1.08) 1.0 
30 day other drug use 1.36 (0.45,4.1 0) 0.6 
Proportion of Neg. Urine Screens 0. 78 (0 .17 ,3.57) 0.7 
Days Prescribed Buprenorphine 1.00 (0 .99,1.01) 0.6 
w 
1\.) 
Table 11: Unadjusted and Adjusted Odds Ratios of Engagement for Patients receiving Buprenorphine in a 
Coordinated Substance Abuse and Primarv Care Out-Patient Treatment P 
Engagement Unadjusted Odds Ratio Adjusted Odds Ratio 
X (95% Cl) p-value X (95% Cl) p-value 
Cocaine: yes vs. no J.19 (OA9,4.12) 0.6 1.096 (0 ~~36,2. 75~) 0.8 
HIV: yes vs. no 1.68 (0 .71 ,3.95) 0.2 1.316 (0.487,3.558) 0.6 
Race: White vs. Non-White 1 .92 (0.81 ,4.55) 0.1 1.792 (0.694,4.696) 0.2 
Female: yes vs. no 1 .17 (0.46,2.97) 0.7 1.255 (0.433,3.640) 0.7 
Age 1.01 (0.97, 1.06) 0.6 1 .001 (0 .950, 1 .055) 1.0 
Housing 1.72 (0.67,4.41) 0.3 
Education 1.07 (0.43,2.67) 0.9 
Employment 2.05 (0.43,9.79) 0.4 
30 day alcohol use 1.81 (0.72,4.56) 0.2 
Mental Illness Diagnosis 1. 70 (0.53,5.46) 0.4 
Individual Counseling Sessions 1.09 (0.99, 1.21) 0.1 
Group Counseling Sessions 1 .08 (1 .00, 1.17) 0.1 
Number of Treatment Episodes 1.02 (0.36,2.91) 1.0 
Number of Urine Screens 1.09 (1 .02, 1.17) 0.0 
30 day other drug use 1.80 (0.75,4.33) 0.2 
Proportion of Neg. Urine Screens 2.48 (0.77,8.01) 0.1 
Days Prescribed Buprenorphine 1.01 (1 .00, 1.01 ) 0.0 
DISCUSSION 
This research found that in patients receiving buprenorphine in an 
integrated primary care and OBOT buprenorphine program, cocaine use at 
baseline was not associated with a decrease in opioid abstinence or treatment 
retention measured at six months. Furthermore, there was no difference 
identified in initiation or engagement between those participants who were 
cocaine positive at baseline as compared with those who were cocaine negative. 
Additionally, this research did not detect covariates typically identified as 
moderating treatment retention and opioid abstinence, including HIV status, race, 
and gender to be significantly associated with the outcomes of this analysis. 
Despite that these covariates of interest were chosen based on a literature 
review of prior research in this field and clinical experience; they did not show 
relevance when determining the effects of the independent variable in this 
particular analysis. Age was the only covariate to show significance at predicting 
a greater likelihood of treatment retention and opioid abstinence, with 1 .11 and 
1.08 times greater likelihood, respectively, of achieving each outcome with an 
increase in one year of age. 
Unique to this research was the use of both HIV positive and HIV negative 
participants in the data analysis. Previous investigations into OBOT 
buprenorphine populations have not included both groups concurrently in 
analyses, but rather used H IV status an inclusion or exclusion criteria based on 
their particular research focus. The current investigation did not show moderation 
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by H IV status on the association between cocaine use at baseline and the 
dependent variables. 
The results of this investigation are both in congruence and in contrast to 
prior research into OBOT buprenorphine programs. Cocaine use within this 
population was marginally less prevalent than the findings of previous research 
with 39%, or 45 out of 116 participants being positive for cocaine use at baseline 
(Sullivan et al., 2011). Prior research has indicated a greater percentage of those 
seeking MMT for opioid dependence to be positive for cocaine at baseline, with a 
range of 40-60% (Sullivan et al., 2011 ). Previous studies in HIV negative 
populations have found baseline cocaine use to be a negative predictor of 
treatment retention and opioid abstinence (Sullivan et al., 201 0; Williamson et al., 
2007); however, this was not supported by data in this investigation. 
Alternatively, subsequent studies in HIV positive populations have found no 
association between baseline cocaine use and treatment retention (Sullivan et 
al., 2011 ), which is similar to the findings of this study. This same investigation 
into H IV positive populations did find baseline cocaine use predicted a 1 .4 times 
greater probability of opioid use during treatment, which is not support by the 
current analysis (Sullivan et al., 2011 ). 
Previous research has noted characteristic differences between cocaine 
positive and cocaine negative subjects, which were not corroborated in the 
current investigation. Sullivan et al. (201 0) noted that among HIV negative 
participants, cocaine use at baseline was associated with higher rates of "drug 
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use, legal , and psychological problems". The current research found no 
difference among the two groups with regard to these parameters. Both cocaine 
positive and cocaine negative participants had similar rates of alcohol use or 
other drug use during the previous 30 days. Additionally, there was a similar rate 
of serious depression diagnoses between the two groups. There was markedly 
few arrests reported for the 30 days prior to study enrollment; however, it was 
split evenly with two arrests in each cohort. 
Counseling rates and frequency in previous studies are varied , and not 
always taken into consideration during data analysis. Some studies have 
reported an inverse relationship between the number of counseling sessions 
attended during the study period to cocaine and opioid abstinence at the end of 
the study period (Montoya et al. , 2005) . This measure could not be assessed 
within this population as both groups experience similar rates of individual and 
group counseling sessions, as well as similar proportions of negative urine 
toxicology screens and opioid abstinence. The effects of mental health 
counseling on the study outcomes cannot be parsed out from the other 
covariates as both cocaine positive and cocaine negative participants had similar 
counseling frequencies and study outcomes. 
The lack of significant findings as compared to previous research in this 
field could be due to the clinical policy of the FAST PATH programs to require 2 
cocaine-free urine tests before starting buprenorphine. This policy could have 
excluded participants who were unable to moderate their cocaine usage from 
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enrolling in the program, or could have significantly increased the time between 
participants being referred to the FAST PATH program and being eligible to 
enroll in the program. These delays could have affected the study outcomes, 
notably the dearth of significant differences between the two cohorts in treatment 
retention, initiation, and engagement. 
Furthermore, the study outcome definitions, opioid abstinence and 
treatment retention, as well as Washington Circle definitions of Initiation and 
Engagement, are not universally employed in all substance abuse treatment 
programs and are more rigorous than other standards. Notably, Sullivan et al. , 
(2011) defined treatment retention as receipt of one dose of buprenorphine within 
a study quarter, which is less strict than the definition of treatment retention used 
in this investigation, no 30 day or greater lapses in contact within the study 
period . These rigid program requirements likely removed subjects from the 
dataset who would have been included in prior studies which did not employ 
these standards. Additionally, by removing these participants from inclusion , it is 
unclear whether the similar treatment retention and opioid abstinence observed 
between the two cohorts was due to an artificial inflation of the cocaine positive 
participants due to the removal of those unable to maintain more regular contact 
with the clinic staff or submit negative cocaine urine toxicology samples. 
There were numerous strengths to this study, including the coordinated 
approach of the FAST PATH program. The close coordination between the HIV 
Care Team and the Primary Care Team ensured all participants received the 
36 
similar care for their opioid dependency as well as the most appropriate primary 
care for their health needs. Additionally, since all treatment was administered at 
BMC, including urine toxicology screenings, counseling, physician , and clin ic 
visits, the similarities in treatment among all participants could be maintained with 
relative ease and without disruptions or delays associated with multi-site 
programs. 
Due to the small sample size, this study was limited in power and unable 
to support logistic regression analysis on all of the covariates identified. Adjusted 
analysis was performed on the primary covariates; however, it is likely due in part 
to the small sample size that no covariates could be identified which affected the 
dependent variables, including cocaine use at baseline. 
Furthermore, cocaine use was only determined at baseline; therefore, the 
effects of in-treatment cocaine use on the study outcomes could not be 
assessed. Previous research has identified differences in outcomes between 
baseline cocaine use and in-treatment cocaine use, which could not be explored 
in this investigation (Sullivan et al. , 2011 ). Additionally, frequency of cocaine use 
was not a parameter used to place participants in the cocaine positive cohort. 
Thus, participants who were infrequent or recreational cocaine users were 
grouped along with habitual cocaine users into the same cohort, which could 
have unforeseen consequences not explored in this analysis. 
This study has numerous implications towards future research integrating 
primary care and OBOT buprenorphine treatment in a coordinated clinical 
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setting. The similar treatment outcomes for both cocaine positive and cocain·e 
negative participants suggest this approach is similarly effective in retaining both 
groups in buprenorphine treatment. Future research within this framework should 
include determining the difference in treatment outcomes for habitual cocaine 
users as compared to infrequent cocaine users. Additionally, among this group, 
those participants who self-reported cocaine negative, but had a positive urine 
toxicology screen for cocaine should be separated to determine if there are any 
unique characteristics to this population which could impact their treatment 
success. 
Although this study did not find a difference in the treatment outcomes of 
cocaine positive versus cocaine negative participants, the research suggests that 
there are other participant characteristics which deseNe further investigation. 
Due to the novelty of OBOT buprenorphine programs, this is a rich area of 
subsequent research to determine how varied groups of opioid dependent 
persons perform within this framework, and the underlying characteristics 
moderating their outcomes. Future research should focus on elucidated these 
nuanced differences and adjusting OBOT buprenorphine programs to better 
accommodate and treat their intended population. 
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